This Program Project is comprised of Clinicians, Clinician/Scientists, and Basic Scientists working to bring together the scientific and clinical resources needed to investigate directly in humans or in human tissues the effects of toxic substances in the environment. This departure from standard approaches to investigation of the toxicology of environmental agents is based on the recognition that the relevance to man of toxicity testing in animals or in vitro systems can be established with certainty only by making critical experiments on humans or on human derived tissues. In Project #1 the characteristics and distribution among human liver samples of purified human liver cytochromes P-450 in patients. Project #3 proposes to use similar biochemical and molecular biologic techniques to investigate a human liver aldo-keto reductase involved in the metabolism of the organochlorine pesticide, chlordecone. In Project #4, biochemical and cytological probes will be used to investigate the mechanisms of toxicity of organophosphates on the nervous system. In Project #5, biochemical and micropuncture techniques will be used to examine mechanisms of glomerular vs. tubular injury by metals. Project #6 is the Clinical Research Core comprised of medical specialty units (neuro-psychiatric, pulmonary, cardiovascular, liver, renal, dermatology, urology, analytical laboratories) capable of evaluating organ specific toxicity. The Core also is comprised of patient populations available for investigation. These include workers with documented over-exposure to cadmium and patients with documented allergic dermatitis to environmental agents. The proposed studies are expected to provide new information about clinical manifestations of toxicity due to environmental agents, insight into the mechanism of injury by these agents, and a greater understanding of some detoxification of enzyme systems. Moreover, we expect this Program to exemplify the utility involving clinical medicine in the study of human toxicology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Program Projects (P01)
Project #
5P01ES004238-03
Application #
3095937
Study Section
Environmental Health Sciences Review Committee (EHS)
Project Start
1987-08-01
Project End
1990-08-31
Budget Start
1989-09-01
Budget End
1990-08-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Quattrochi, L C; Yockey, C B; Barwick, J L et al. (1998) Characterization of DNA-binding proteins required for glucocorticoid induction of CYP3A23. Arch Biochem Biophys 349:251-60
Fontana, R J; deVries, T M; Woolf, T F et al. (1998) Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Br J Clin Pharmacol 46:221-8
Guzelian, P S (1997) Relevance of rat liver tumors to human hepatic and endometrial cancer. Semin Oncol 24:S1-105-S1-21
Zhang, Z Y; Kerr, J; Wexler, R S et al. (1997) Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. Thromb Res 88:389-98
Kaminsky, L S; Zhang, Z Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
Brown, S E; Quattrochi, L C; Guzelian, P S (1997) Characterization of a pretranscriptional pathway for induction by phenobarbital of cytochrome P450 3A23 in primary cultures of adult rat hepatocytes. Arch Biochem Biophys 342:134-42
Sullivan-Klose, T H; Ghanayem, B I; Bell, D A et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-9
Barwick, J L; Quattrochi, L C; Mills, A S et al. (1996) Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol 50:10-6
Haehner, B D; Gorski, J C; Vandenbranden, M et al. (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-9
Fontana, R J; Turgeon, D K; Woolf, T F et al. (1996) The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 23:1429-35

Showing the most recent 10 out of 39 publications